121 related articles for article (PubMed ID: 35089073)
21. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.
Morgan J; Hoekstra AV; Chapman-Davis E; Hardt JL; Kim JJ; Buttin BM
Gynecol Oncol; 2009 Aug; 114(2):293-8. PubMed ID: 19476987
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J; Hu B; Gui YC; Tan ZB; Xu JW
Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
[TBL] [Abstract][Full Text] [Related]
23. Correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis.
Luo JH; Zhou J; Gao Y
Asian Pac J Trop Med; 2013 Jul; 6(7):516-9. PubMed ID: 23768821
[TBL] [Abstract][Full Text] [Related]
24. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.
Fu B; Yan P; Zhang S; Lu Y; Pan L; Tang W; Chen S; Chen S; Zhang A; Liu W
Dis Markers; 2018; 2018():6437104. PubMed ID: 29849824
[TBL] [Abstract][Full Text] [Related]
25. γ-Synuclein Expression Is a Malignant Index in Oral Squamous Cell Carcinoma.
Cheng JC; Chiang MT; Lee CH; Liu SY; Chiu KC; Chou YT; Huang RY; Huang SM; Shieh YS
J Dent Res; 2016 Apr; 95(4):439-45. PubMed ID: 26661712
[TBL] [Abstract][Full Text] [Related]
26. Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis.
He N; Feng G; Zhang C; Wu F; Zhang T; Yang Y
Mol Med Rep; 2020 Oct; 22(4):2705-2714. PubMed ID: 32945374
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Value of Methylated
Xie L; Jiang X; Li Q; Sun Z; Quan W; Duan Y; Li D; Chen T
Front Oncol; 2018; 8():247. PubMed ID: 30013949
[TBL] [Abstract][Full Text] [Related]
28. Methylated Septin9 (m
Loomans-Kropp HA; Song Y; Gala M; Parikh AR; Van Seventer EE; Alvarez R; Hitchins MP; Shoemaker RH; Umar A
Cancer Res Commun; 2022 Feb; 2(2):90-98. PubMed ID: 35992328
[TBL] [Abstract][Full Text] [Related]
29. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients.
Yang X; Xu ZJ; Chen X; Zeng SS; Qian L; Wei J; Peng M; Wang X; Liu WL; Ma HY; Gong ZC; Yan YL
World J Gastroenterol; 2019 May; 25(17):2099-2109. PubMed ID: 31114136
[TBL] [Abstract][Full Text] [Related]
30. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
32. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.
Liu H; Liu W; Wu Y; Zhou Y; Xue R; Luo C; Wang L; Zhao W; Jiang JD; Liu J
Cancer Res; 2005 Sep; 65(17):7635-43. PubMed ID: 16140929
[TBL] [Abstract][Full Text] [Related]
33. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
[TBL] [Abstract][Full Text] [Related]
34. [Expression and clinical significance of plasma methylated SEPT 9 gene in patients with primary liver cancer].
He N; Feng G; Zhang FN; Hao S; Li R; Zhao ZQ; Tian YW; Yan HL
Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):265-270. PubMed ID: 37137852
[No Abstract] [Full Text] [Related]
35. Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Min L; Ma RL; Yuan H; Liu CY; Dong B; Zhang C; Zeng Y; Wang L; Guo JP; Qu LK; Shou CC
Asian Pac J Cancer Prev; 2015; 16(7):2819-26. PubMed ID: 25854368
[TBL] [Abstract][Full Text] [Related]
36. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
37. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
[TBL] [Abstract][Full Text] [Related]
38. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
Zhao W; Liu H; Liu W; Wu Y; Chen W; Jiang B; Zhou Y; Xue R; Luo C; Wang L; Jiang JD; Liu J
Int J Oncol; 2006 May; 28(5):1081-8. PubMed ID: 16596223
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of synuclein-γ levels by novel monoclonal antibody in saliva and cancer tissues from oral squamous cell carcinoma patients.
Wang K; Shen Y; Xu J; Li Z; Liu Y; Yu C; Peng L; Zheng J; Zeng Y
Neoplasma; 2020 May; 67(3):707-713. PubMed ID: 32202903
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation of
Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
